A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.

Also called NCT05737940

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 260 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
  • Parexel Registry lists this organization as a collaborator
Registry
  • NCT NCT05737940
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Canada, China, Czechia, Denmark, Germany, Italy, Japan, Netherlands, Poland, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05737940. Randomized; triple masking; primary purpose treatment. Start 2023-04-24 (actual); primary completion 2025-07-15 (actual). Results posted on 2026-10-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Acronym
Re-PHIRE
Condition
Pulmonary Hypertension (World Health Organization Group 2)
Condition
Heart Failure
Intervention (Drug)
AZD3427
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Parexel (class: industry)

Record details

Record id
cardio:ct-nct05737940
Content hash
755aa3198779adc5725d9cf26c90e52d5d6090a8e0a23e8cebc40c0dd396a29d